Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques

The European Medicines Agency received recently the first marketing authorization application for a biosimilar monoclonal antibody (mAb) and adopted the final guidelines on biosimilar mAbs and Fc-fusion proteins. The agency requires high similarity between biosimilar and reference products for appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayoub, Daniel, Jabs, Wolfgang, Resemann, Anja, Evers, Waltraud, Evans, Catherine, Main, Laura, Baessmann, Carsten, Wagner-Rousset, Elsa, Suckau, Detlev, Beck, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851223/
https://www.ncbi.nlm.nih.gov/pubmed/23924801
http://dx.doi.org/10.4161/mabs.25423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851223/
https://www.ncbi.nlm.nih.gov/pubmed/23924801
http://dx.doi.org/10.4161/mabs.25423

Ejemplares similares